We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+32.66%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.98B
AUM Growth
+$533M
Cap. Flow
+$206M
Cap. Flow %
10.36%
Top 10 Hldgs %
47.31%
Holding
123
New
37
Increased
37
Reduced
31
Closed
16

Top Buys

Rank Stock Value
1
AVTR icon
Avantor
AVTR
+$27.7M
2
GSK icon
GSK
GSK
+$26.1M
3
ABVX
Abivax
ABVX
+$25.2M
4
EXAS
Exact Sciences
EXAS
+$19.4M
5
DHR icon
Danaher
DHR
+$19.1M

Top Sells

Rank Stock Value
1
ZIMV
ZimVie
ZIMV
+$39.4M
2
NTRA icon
Natera
NTRA
+$38.6M
3
QURE icon
uniQure
QURE
+$31.4M
4
RVTY icon
Revvity
RVTY
+$22.2M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.79%
2 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INMD icon
101
InMode
INMD
$872M
$910K 0.05%
+61,938
New +$912K
WHWK
102
Whitehawk Therapeutics
WHWK
$183M
$630K 0.03%
+260,259
New +$597K
EDIT icon
103
Editas Medicine
EDIT
$399M
$596K 0.03%
+290,919
New +$840K
SLQT icon
104
SelectQuote
SLQT
$114M
$504K 0.03%
+357,661
New +$598K
RVP icon
105
Retractable Technologies
RVP
$20.4M
$449K 0.02%
580,919
+217,604
+60% +$188K
SSII
106
SS Innovations International
SSII
$695M
$428K 0.02%
+75,358
New +$521K
CBLL
107
CeriBell Inc
CBLL
$642M
$375K 0.02%
17,094
– –
DYN icon
108
Dyne Therapeutics
DYN
$4.04B
– –
-10,000
Closed -$127K
ETNB
109
DELISTED
89bio
ETNB
– –
-392,441
Closed -$5.77M
GOSS icon
110
Gossamer Bio
GOSS
$66.5M
– –
-925,233
Closed -$2.43M
KRRO icon
111
Korro Bio
KRRO
$153M
– –
-20,856
Closed -$999K
KURA icon
112
Kura Oncology
KURA
$922M
– –
-263,628
Closed -$2.33M
MIRM icon
113
Mirum Pharmaceuticals
MIRM
$6.89B
– –
-49,314
Closed -$3.62M
MRUS
114
DELISTED
Merus
MRUS
– –
-48,054
Closed -$4.52M
NKTR icon
115
Nektar Therapeutics
NKTR
$2.39B
– –
-49,890
Closed -$2.84M
NVO
116
Novo Nordisk
NVO
$216B
– –
-217,708
Closed -$12.1M
REPL icon
117
Replimune Group
REPL
$814M
– –
-59,992
Closed -$251K
RGEN icon
118
Repligen
RGEN
$7.44B
– –
-105,087
Closed -$14M
RNAM
119
DELISTED
Avidity Biosciences
RNAM
– –
-302,911
Closed -$13.2M
UTHR icon
120
PUT
United Therapeutics
UTHR
$26.3B
– –
-16,200
Closed -$6.79M
ZIMV
121
DELISTED
ZimVie
ZIMV
– –
-2,079,380
Closed -$39.4M
ATYR
122
PUT
aTyr Pharma
ATYR
$46.4M
– –
-658,000
Closed -$475K
PVLA
123
Palvella Therapeutics
PVLA
$1.98B
– –
-11,343
Closed -$711K
1 2 3 4
5

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Eversept Partners held 123 positions worth $1.98B, up 37% from $1.45B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners deployed $206M of net new capital in Q4 2025, opening 37 new positions and adding to 37 existing holdings. Its largest new stake was Exact Sciences: 241,678 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 90% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Natera, an estimated $38.6M trimmed.

  • Eversept Partners's largest Q4 2025 buy was Exact Sciences: 241,678 shares worth $24.5M.
  • Eversept Partners added most to Avantor in Q4 2025, an estimated $27.7M increase.
  • Eversept Partners's biggest Q4 2025 reduction was Natera, cutting an estimated $38.6M.
  • Eversept Partners fully exited ZimVie in Q4 2025, selling an estimated $39.4M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.98B portfolio in Q4 2025.
  • Eversept Partners opened 37 new positions and closed 16 in Q4 2025.
  • Eversept Partners's portfolio value rose 37% quarter-over-quarter to $1.98B.

Based on Eversept Partners's 13F filing for Q4 2025, filed 17 Feb 2026.